 | • レポートコード：MRC2203A384 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の皮膚T細胞リンパ腫市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（菌状息肉腫（MF）、セザリー症候群（SS）、その他）分析、治療別（放射線治療、化学療法、免疫療法、標的療法、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の皮膚T細胞リンパ腫市場規模：種類別（菌状息肉腫（MF）、セザリー症候群（SS）、その他） ・世界の皮膚T細胞リンパ腫市場規模：治療別（放射線治療、化学療法、免疫療法、標的療法、その他） ・世界の皮膚T細胞リンパ腫市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Bausch Health Companies Inc.、Celgene Corporation、Helsinn Healthcare SA、…） ・市場機会・将来傾向 |
Certain factors that are driving the market growth include rise in lymphoma cancer incidence and growing geriatric population.
Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. The two most common types of CTCL are mycosis fungoides (MF), which is slow-growing in the early stages, and Sézary Syndrome (SS), which is a more aggressive form of CTCL. According to Cutaneous Lymphoma Foundation, CTCL is a rare family of diseases, with approximately 3,000 new cases reported in the United States every year and about 16,000 – 20,000 Americans have mycosis fungoides. CTCL is more common in patients older than 50 years of age compared to younger people and it develops more often in men than in women, with the highest incidence rates being reported amongst African-Americans.
Key Market Trends
Mycosis Fungoides Segment is Expected to Register a Significant Growth in the Forecast Years
By type, the market has been segmented into Mycosis Fungoides (MF), Sezary Syndrome (SS) and others. Mycosis Fungoides is the most frequent type of cutaneous T-cell lymphoma which usually involves the skin and grows slowly over many years. It is very difficult to diagnose, especially in the early stages. MF is more common in men compared to women, in blacks compared to whites, and in older population compared to younger people. In addition, sezary syndrome is considered to be the second most common type of CTCL and characterized by the presence of lymphoma cells in the blood.
North America dominates the Cutaneous T- cell Lymphoma Market
North America dominates the market owing to the upsurge in the demand for progressive treatment options and early adoption of new technologies. Cutaneous T-cell Lymphoma (CTCL) is the rare form of T-cell lymphoma. There are about 3,000 new cases of CTCL in the U.S. each year. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.
Competitive Landscape
The market studied is moderately competitive and consists of several major players. Some of the key players in the cutaneous T-cell lymphoma market includes Bausch Health Companies Inc., Celgene Corporation, Helsinn Healthcare SA, Kyowa Hakko Kirin Co., Ltd., Merck & Co. Inc., Seattle Genetics, and Soligenix, Inc., which are having presence internationally and provide these products across the globe.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Lymphoma Cancer Incidence
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Mycosis Fungoides (MF)
5.1.2 Sezary Syndrome (SS)
5.1.3 Others
5.2 By Treatment
5.2.1 Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Targeted therapy
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch Health Companies Inc.
6.1.2 Celgene Corporation
6.1.3 Helsinn Healthcare SA
6.1.4 Kyowa Hakko Kirin Co., Ltd.
6.1.5 Merck & Co., Inc.
6.1.6 Seattle Genetics
6.1.7 Soligenix, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS